Phase 3 trial in 122 ambulatory males aged 4-7 with Duchenne muscular dystrophy: fordadistrogene movaparvovec gene therapy did not improve NSAA score at 52 weeks vs placebo (difference 0.09; p=0.91; 92 analysed); serious adverse events 32% vs 14%.
RCTn = 122
Muntoni et al. Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study